Anavex (AVXL): Price-to-Revenue Ratio
The speculative nature of neurodrug development requires regulatory approval. Anavex Life Sciences focuses on the breakthrough application of Blarcamesine to combat Parkinson's and Alzheimer's diseases, scaling Phase 3 trials. The historical P/S trend confirms the sales value dynamics, where reflects the latest metric value. High scientific risks and fierce competition for leadership in brain degeneration therapy create significant business challenges.
Anavex Life Sciences (AVXL) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- issuer book value statistics:
- debt obligations and liquidity statistics:
Debt to Capital Anavex Life Sciences|AVXL - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital anavex.com|AVXL - Company Debts|Debts to Net Assets Anavex Life Sciences Corp|AVXL - Company Long-Term Debts|Company Current Liabilities Anavex Life Sciences|Interim Coverage Ratio anavex.com
- net income and valuation ratios data:
AVXL - Net Profit|Expected Net Profit Anavex Life Sciences|AVXL - Price to Earnings Ratio|Price to Future Earnings Ratio Anavex Corp|AVXL - PEG Multiple|Enterprise Value to EBITDA Ratio Anavex Life Sciences Corp|AVXL - Operating profit EBITDA|Net earnings per one share for the last twelve months Anavex Life Sciences|AVXL - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months anavex.com|AVXL - Earnings growth in current year|Earnings growth forecast for next year Anavex Life Sciences
- issuer revenue and sales details:
Fundamental company analysis:AVXL, Anavex Life Sciences Corp.
The P/S ratio determines the market value of one dollar of revenue, allowing for an assessment of the premium paid for a business relative to its current operating income. By analyzing the price-to-sales ratio, an investor can gauge market expectations for the monetization of Anavex Life Sciences (AVXL) patents, where a high valuation is driven by long-term demand for neurodegenerative disease therapies.
Competing companies
BIIB (Biogen) - Market Capitalization-to-Revenue Ratio|P/S Multiple NBIX (Neurocrine Corp)|Regencell Bioscience - Price-to-Revenue Ratio|Axsome Therapeutics - P/S Multiple|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Price-to-Revenue Ratio|Price to Sales Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - P/S Multiple|CPRX: Market Capitalization-to-Revenue Ratio|P/S Multiple DNLI|Price-to-Revenue Coefficient Harmony Biosciences|Biohaven Ltd - Market Cap to Revenue|P/S Multiple Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Market Cap to Revenue|Price-to-Revenue Coefficient Praxis Corp PRAX|CBLL: P/S Multiple|Prothena Biosciences - Market Capitalization-to-Revenue Ratio|ALEC (alector.com) - P/S Multiple|Market Cap to Revenue Ratio ANNX (Annexon Biosciences)|Price-to-Revenue Ratio Omeros Corporation (OMER)|Neurogene Corp - Market Cap to Revenue Ratio|Price-to-Revenue Ratio AC Immune S.A. ACIU|Price-to-Revenue Coefficient Voyager Therapeutics (VYGR)|Neumora - P/S Multiple|Price-to-Sales Ratio SCLX|Tevogen Bio Inc. (TVGN) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio ACOG|CGTX (cogrx.com) - P/S Multiple|Market Cap to Revenue inhibikase.com (IKT)|Price-to-Revenue Ratio Cassava Sciences Inc (SAVA)|Price-to-Revenue Coefficient Assertio|P/S Multiple COYA (Coya Therapeutics, Inc.)|Market Cap to Sales Volume VTGN (VistaGen Therapeutics Inc)|OVID: Market Cap to Revenue|ABOS: Price-to-Revenue Ratio|CervoMed (CRVO) - Price-to-Revenue Ratio|Price to Sales Alterity Therapeutics Ltd (ATHE)|CLNN (Clene) - P/S Multiple|Market Cap to Revenue Ratio PEPG (PepGen)|Market Cap to Revenue JUNS (Jupiter Neurosciences, Inc.)|P/S Multiple relmada.com (RLMD)|Price-to-Revenue Ratio Annovis Bio Corp ANVS|GRCE: Market Cap to Revenue Ratio|AIFF - Price-to-Revenue Ratio|KLTO (anewmeds.com) - Market Cap to Revenue Ratio|NRSN (NeuroSense Therapeutics Ltd.) - Market Cap to Revenue|revivapharma.com - Market Capitalization-to-Revenue Ratio|MTVA (metaviatx.com) - P/S Multiple|NRXS: Market Capitalization-to-Revenue Ratio|P/S Multiple HSDT|PASG - Price to Sales|P/S Multiple NEUP (Neuphoria Therapeutics)|NERV: Market Cap to Revenue Ratio|ATHA: Market Cap to Revenue|Addex Therapeutics Ltd - Market Cap to Sales Volume|Alzamend Neuro, Inc. (ALZN) - Price-to-Revenue Ratio|CYCN (Cyclerion Therapeutics Inc.) - Price-to-Revenue Ratio|Market Cap to Revenue PTIX|KTTA: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue CRGT (Cortigent Medical)|ATXI (Avenue Therapeutics, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Brainstorm Cell Therapeutics, Inc. BCLI|Market Capitalization-to-Revenue Ratio CARA|chromocell.com - P/S Multiple|Price-to-Sales Ratio ELYM|ITCI: P/S Multiple|Price to Sales Longboard Pharmaceuticals, Inc. (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|P/S Multiple NRBO|SAGE: Price-to-Sales Ratio|Synaptogenix Inc. - Market Cap to Revenue|Market Cap to Sales Volume TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - P/S Multiple|Anew Medical (WENA) - Market Cap to Revenue|CERE (Cerevel Corp) - Market Cap to Revenue
